Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AIkido Pharma SPEX

Healthcare Biotechnology
AIkido Pharma Inc is a United States-based biotechnology company. The company is engaged in the development of small-molecule anti-cancer therapeutics. The company's drug portfolio includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).

Recent & Breaking News (NDAQ:SPEX)

AIkido Pharma Inc. Announces Closing of $14.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

PR Newswire April 15, 2020

AIkido Pharma Inc. Announces $14.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

PR Newswire April 14, 2020

AIkido Pharma Executes Exclusive World-Wide License to Broad Spectrum Antiviral Drug Platform, Includes Coronavirus

PR Newswire April 14, 2020

AIkido Pharma Inc. Provides Update on Timing of Record Date and Anticipated Distribution Date for Dividend Distribution

PR Newswire March 27, 2020

AIkido Issues Shareholder Update on COVID-19, Dividend, And Path Forward

PR Newswire March 26, 2020

AIKido Pharma Inc. Adopts Plan to Preserve Valuable Tax Assets

PR Newswire March 23, 2020

Shareholder Update from AIkido Pharma Incorporated on Coronavirus Option

PR Newswire March 18, 2020

Spherix Completes Name Change to AIkido Pharma Inc.

PR Newswire March 13, 2020

Spherix Announces Closing of $5.75 Million Registered Direct Offering Priced At-the-Market

PR Newswire March 10, 2020

Shareholder Update on Treatment for Coronavirus Optioned by Spherix

PR Newswire March 10, 2020

Spherix Announces $5.75 Million Registered Direct Offering Priced At-the-Market

PR Newswire March 9, 2020

Treatment for Coronavirus Optioned by Spherix

PR Newswire March 6, 2020

Spherix Incorporated Changing Name to AIkido Pharma Inc. to Reflect Increased Focus on Artificial Intelligence and Machine Learning in Drug Development

PR Newswire March 5, 2020

Spherix Moves Dividend Record Date to Friday, March 6, 2020

PR Newswire March 4, 2020

Spherix Executes Machine Learning Scientific Research Agreement

PR Newswire March 3, 2020

Spherix Announces Pricing of $7.5 Million Public Offering

PR Newswire March 3, 2020

Spherix Attends Artificial Intelligence and Machine Learning Pharmaceutical Development Conference

PR Newswire February 25, 2020

Spherix Announces a Special Dividend Distribution

PR Newswire February 23, 2020

Spherix Issues Letter to Shareholders

PR Newswire February 14, 2020

Spherix Launches Newly Redesigned Website

PR Newswire January 21, 2020